Anamorelin

Anamorelin is an orally administered medication classified as a ghrelin receptor agonist. It is primarily studied and used in the medical context for the treatment of anorexia, cachexia, and involuntary weight loss, particularly in patients with cancer. Cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle mass with or without loss of fat mass. Anamorelin aims to counteract these conditions by stimulating the ghrelin pathway, a system in the body involved in regulating appetite and metabolism. It is not currently approved in all regions globally for general use in all populations experiencing weight loss. In some jurisdictions, it is approved specifically for the treatment of cancer cachexia. Anamorelin acts by mimicking the action of endogenous ghrelin, often referred to as the 'hunger hormone.' By binding to and activating the ghrelin receptor, it can stimulate appetite, improve food intake, and promote weight gain, primarily through increases in lean body mass. The development of anamorelin represents an effort to address the significant challenge of managing cachexia and its associated symptoms, which can severely impact patient quality of life and treatment outcomes. Its half-life is approximately 7 hours, meaning it typically takes about 7 hours for half of the administered dose to be eliminated from the body. This relatively short half-life guides its dosing frequency. Anamorelin is not considered a controlled substance.